HER2-positive breast cancer with brain metastasis, long responder to lapatinib therapy
We report the case of a 45-year-old patient diagnosed, after four years from the initial diagnosis of infiltrating ductal carcinoma, with lymph node, hepatic, pulmonary and bone diseases deriving from HER2-positive breast cancer. While the association docetaxel + trastuzumab led to a partial respon...
Main Author: | Chiara Saggia |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2018-06-01
|
Series: | AboutOpen |
Subjects: | |
Online Access: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/160 |
Similar Items
-
HER2-positive breast cancer with brain metastasis: long-lasting response after lapatinib treatment
by: Alessia D'Alonzo, et al.
Published: (2018-06-01) -
Lunga sopravvivenza di una paziente con carcinoma mammario HER2-positivo, in trattamento con lapatinib
by: Anna Gambaro
Published: (2017-12-01) -
Good control of diffuse brain metastasis with lapatinib plus capecitabine in a patient with HER2-positive breast cancer
by: Giovanni Faggioni
Published: (2018-06-01) -
Sopravvivenza a lungo termine in paziente trattata con lapatinib e capecitabina
by: Carlo Mulas
Published: (2017-12-01) -
Long-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years
by: Salvatore Turano, et al.
Published: (2018-09-01)